WO2004035746A3 - Susceptibility gene for myocardial infarction - Google Patents

Susceptibility gene for myocardial infarction Download PDF

Info

Publication number
WO2004035746A3
WO2004035746A3 PCT/US2003/032805 US0332805W WO2004035746A3 WO 2004035746 A3 WO2004035746 A3 WO 2004035746A3 US 0332805 W US0332805 W US 0332805W WO 2004035746 A3 WO2004035746 A3 WO 2004035746A3
Authority
WO
WIPO (PCT)
Prior art keywords
myocardial infarction
susceptibility gene
locus
gene
susceptibility
Prior art date
Application number
PCT/US2003/032805
Other languages
French (fr)
Other versions
WO2004035746A2 (en
Inventor
Anna Helgadottir
Jeffrey R Gulcher
Andrei Manolescu
Original Assignee
Decode Genetics Ehf
Anna Helgadottir
Jeffrey R Gulcher
Andrei Manolescu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf, Anna Helgadottir, Jeffrey R Gulcher, Andrei Manolescu filed Critical Decode Genetics Ehf
Priority to AU2003290527A priority Critical patent/AU2003290527A1/en
Priority to CA002502359A priority patent/CA2502359A1/en
Priority to EP03783063A priority patent/EP1562973A4/en
Priority to US10/829,674 priority patent/US7507531B2/en
Publication of WO2004035746A2 publication Critical patent/WO2004035746A2/en
Priority to US10/587,412 priority patent/US20080293750A1/en
Publication of WO2004035746A3 publication Critical patent/WO2004035746A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Linkage of Myocardial Infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by association analysis to be a susceptibility gene for MI. Pathway targeting for drug delivery and diagnosis applications in identifying those have MI or at risk of developing MI, in particular are described.
PCT/US2003/032805 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction WO2004035746A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003290527A AU2003290527A1 (en) 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction
CA002502359A CA2502359A1 (en) 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction
EP03783063A EP1562973A4 (en) 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction
US10/829,674 US7507531B2 (en) 2002-10-17 2004-04-22 Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US10/587,412 US20080293750A1 (en) 2002-10-17 2005-01-31 Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41943202P 2002-10-17 2002-10-17
US60/419,432 2002-10-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US76954204A Continuation-In-Part 2002-10-17 2004-01-30

Publications (2)

Publication Number Publication Date
WO2004035746A2 WO2004035746A2 (en) 2004-04-29
WO2004035746A3 true WO2004035746A3 (en) 2005-04-28

Family

ID=32108082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032805 WO2004035746A2 (en) 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction

Country Status (4)

Country Link
EP (1) EP1562973A4 (en)
AU (1) AU2003290527A1 (en)
CA (1) CA2502359A1 (en)
WO (1) WO2004035746A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
JP2007538003A (en) * 2004-01-30 2007-12-27 デコード ジェネティクス イーエッチエフ． Susceptibility gene for myocardial infarction, stroke and peripheral arterial occlusion disease, treatment method
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
EP1983062A1 (en) * 2007-04-18 2008-10-22 Siemens Healthcare Diagnostics Inc. Single nucleotide polymorphisms associated with susceptibiliy to cardiovascular disease
WO2007014338A2 (en) * 2005-07-26 2007-02-01 Siemens Medical Solutions Diagnostics Single nucleotide polymorphisms associated with susceptibility to cardiovascular disease
SI1976828T1 (en) 2005-12-29 2017-07-31 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
WO2008102380A1 (en) 2007-02-21 2008-08-28 Decode Genetics Ehf Genetic susceptibility variants associated with cardiovascular disease
US7883851B2 (en) 2007-05-02 2011-02-08 Board Of Regents, The University Of Texas System Common allele on chromosome 9 associated with coronary heart disease
CZ2009872A3 (en) * 2009-12-22 2011-04-20 Ústav informatiky AV CR, v.v.i. Centrum biomedicínské informatiky Method of determining prognosis of patients with primary myocardial infarction and oligonucleotide chip for such determination
US20220049306A1 (en) * 2011-08-05 2022-02-17 Genincode Uk, Ltd. Cardiovascular disease
EP2968359B1 (en) 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase
AU2019278935A1 (en) 2018-05-31 2020-12-10 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE SNP [online] 10 October 2000 (2000-10-10), XP002983957, Database accession no. RS1323898 *
See also references of EP1562973A4 *

Also Published As

Publication number Publication date
CA2502359A1 (en) 2004-04-29
EP1562973A4 (en) 2007-01-03
EP1562973A2 (en) 2005-08-17
WO2004035746A2 (en) 2004-04-29
AU2003290527A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2004035746A3 (en) Susceptibility gene for myocardial infarction
WO2004035741A3 (en) Susceptibility gene for myocardial infarction; methods of treatment
Costa-Guda et al. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas
WO1999052942A3 (en) Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma
WO2006050475A3 (en) Identification of dysregulated genes in patients with neurological diseases
WO2004005458A3 (en) Functional sites
WO2004024757A3 (en) Modified pna molecules
WO2005090393A3 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
Hocharoen et al. Metallotherapeutics: novel strategies in drug design
WO2005108613A3 (en) Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5
WO2007019178A3 (en) Corn protein concentrates
WO2008112898A3 (en) Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
WO2003016563A3 (en) Novel molecular target for neurotoxicity
WO2005075022A3 (en) Susceptibility gene for myocardial infraction, stroke, and paod; methods of treatment
WO2006026051A3 (en) Selections of genes and methods of using the same for diagnosis, prognosis and for targeting the therapy of neuroblastoma
WO2004041216A3 (en) Ptpn11 (shp-2) mutations and cancer
WO2008065544A3 (en) Genetic predictors of risk for type 2 diabetes mellitus
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
Ashavaid et al. Design of allele specific PCR for rapid detection of CYP3A5 (A6986G) and Mdr-1 (C3435T) polymorphisms
WO2004041193A3 (en) HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5
WO2003054143A3 (en) Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO2003034818A1 (en) Sgrf genetically modified nonhuman animal
WO2005072150A3 (en) Ldlr genetic markers associated with age of onset of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2502359

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003290527

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003783063

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003783063

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP